How would you define the success of Medable's eConsent solution for clinical trials?

Introduction

Defining the success of Medable's eConsent solution for clinical trials requires a comprehensive approach that considers multiple stakeholders and metrics. To address this product success metrics challenge effectively, I'll follow a structured framework covering core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

Medable's eConsent solution is a digital platform designed to streamline the informed consent process in clinical trials. It allows participants to review study information, ask questions, and provide consent electronically, improving efficiency and compliance.

Key stakeholders include:

1. Clinical trial participants
2. Pharmaceutical companies and research organizations
3. Clinical research coordinators and investigators
4. Regulatory bodies (e.g., FDA, EMA)

User flow:

1. Participant receives invitation to review study information
2. Reviews multimedia content explaining the trial
3. Completes comprehension quiz to ensure understanding
4. Electronically signs consent form
5. Receives copy of signed document

The eConsent solution fits into Medable's broader strategy of digitizing and decentralizing clinical trials, making them more accessible and efficient. Compared to competitors like DocuSign and SignNow, Medable's solution is specifically tailored for clinical trials, offering features like multimedia content and comprehension assessments.

Product Lifecycle Stage: Growth phase. The solution has proven its value but is still expanding its market share and feature set.

Software-specific context:

• Platform: Cloud-based, mobile-responsive web application
• Integration points: Electronic Data Capture (EDC) systems, Clinical Trial Management Systems (CTMS)
• Deployment model: Software-as-a-Service (SaaS)